Karolinska Development (KDEV) Q4 2024 earnings summary

Executive summary

• Net loss for 2024 was SEK -8.1 million, down from a profit of SEK 5.4 million in 2023; Q4 net profit was SEK 18.6 million, up from SEK -1.9 million in Q4 2023.

• Earnings per share for 2024 were SEK -0.03, compared to SEK 0.02 in 2023; Q4 EPS was SEK 0.07, up from SEK -0.01 in Q4 2023.

• Portfolio companies advanced clinical programs, secured major financings, and reported positive data in key therapeutic areas.

• Organizational changes and divestment of OssDsign shares improved liquidity and operational efficiency.

Financial highlights

• Revenue for 2024 was SEK 1.8 million, down from SEK 2.0 million in 2023; Q4 revenue was SEK 0.5 million, flat year-over-year.

• Change in fair value of portfolio for 2024 was SEK 1.6 million, down from SEK 15.2 million in 2023; Q4 change was SEK 18.7 million, up from SEK 6.6 million in Q4 2023.

• Net asset value at year-end was SEK 1,245.0 million (SEK 4.6 per share), slightly down from SEK 1,253.4 million in 2023.

• Cash and cash equivalents at year-end were SEK 42.0 million, down from SEK 85.3 million in 2023.

• Investments in portfolio companies totaled SEK 62.0 million in 2024, down from SEK 103.0 million in 2023.

Outlook and guidance

• Several portfolio companies are expected to present Phase 1 and Phase 2 data in 2025–2026; Dilafor and BOOST Pharma are preparing for Phase 3 studies.

• No dividend proposed for 2024.

• Enhanced liquidity and cost reductions position the company to support ongoing portfolio development.